Comment
doi: 10.1016/S1470-2045(21)00298-9.
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply
Affiliations
- PMID: 34087147
- DOI: 10.1016/S1470-2045(21)00298-9
Item in Clipboard
Comment
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply
Lancet Oncol.
2021 Jun.
No abstract available
Conflict of interest statement
I received institutional research funding from Millennium, Pfizer/EMD Serono, and Sanofi; advisory or consulting fees from Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Merck, Novartis, Pfizer, and Pierre Fabre; honoraria from UpToDate; stock ownership of Rainier; and travel, accommodation, or expenses support from Ipsen, MSD Oncology, and Pfizer.
Comment on
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
-
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma.Lancet Oncol. 2021 Jun;22(6):e236. doi: 10.1016/S1470-2045(21)00205-9. Lancet Oncol. 2021. PMID: 34087145 No abstract available.
-
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma.Lancet Oncol. 2021 Jun;22(6):e237. doi: 10.1016/S1470-2045(21)00202-3. Lancet Oncol. 2021. PMID: 34087146 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
